Serial Randomized Comparison of Strut Coverage of Everolimus- and First-Generation Sirolimus-Eluting Stents

Canadian Journal of Cardiology

Volumn 31, Issue 6, 2015, Pages 723-730

  Kim, Jung Sun ^a,b   Kim, Jeong Hun ^a   Shin, Dong Ho ^a,b   Kim, Byeong Keuk ^a,b   Ko, Young Guk ^a,b   Choi, Donghoon ^a,b   Jang, Yangsoo ^a,b   Hong, Myeong Ki ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; RAPAMYCIN;

ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EVEROLIMUS ELUTING CORONARY STENT; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; SIROLIMUS ELUTING CORONARY STENT; TREATMENT RESPONSE; WOUND HEALING; AGE; AGED; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; CORONARY STENOSIS; DRUG ELUTING STENT; FEMALE; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; PROSTHESIS; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGRESSION ANALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84929839193     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.01.002     Document Type: Article

References (26)

1. Finn A.V., Nakazawa G., Joner M., et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007, 27:1500-1510.
2. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007, 115:2435-2441.
3. Simard T., Hibbert B., Ramirez F.D., et al. The evolution of coronary stents: a brief review. Can J Cardiol 2014, 30:35-45.
4. Kim J.S., Kim B.K., Jang I.K., et al. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). Am Heart J 2012, 163:601-607.
5. Tearney G.J., Regar E., Akasaka T., et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. JAm Coll Cardiol 2012, 59:1058-1072.
6. Kim J.S., Jang I.K., Fan C., et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv 2009, 2:1240-1247.
7. Bezerra H.G., Attizzani G.F., Sirbu V., et al. Optical coherence tomography versus intravascular ultrasound to evaluate coronary artery disease and percutaneous coronary intervention. JACC Cardiovasc Interv 2013, 6:228-236.
8. Kim S.J., Lee H., Cho J.M., et al. Comparison of zotarolimus-eluting stent and everolimus-eluting stent for vascular healing response: serial 3-month and 12-month optical coherence tomography study. Coron Artery Dis 2013, 24:431-439.
9. Kim S., Kim J.S., Shin D.H., et al. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography. Am J Cardiol 2013, 111:1-5.
10. Takano M., Inami S., Jang I.K., et al. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol 2007, 99:1033-1038.
11. Tanigawa J., Barlis P., Dimopoulos K., et al. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardiol 2009, 134:180-188.
12. Kim B.K., Shin D.H., Kim J.S., et al. Optical coherence tomography-based evaluation of malapposed strut coverage after drug-eluting stent implantation. Int J Cardiovasc Imaging 2012, 28:1887-1894.
13. Kume T., Akasaka T., Kawamoto T., et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol 2006, 97:1713-1717.
14. Kim J.S., Hong M.K., Shin D.H., et al. Quantitative and qualitative changes in DES-related neointimal tissue based on serial OCT. JACC Cardiovasc Imaging 2012, 5:1147-1155.
15. Kim B.K., Hong M.K., Shin D.H., et al. Optical coherence tomography analysis of strut coverage in biolimus- and sirolimus-eluting stents: 3-month and 12-month serial follow-up. Int J Cardiol 2013, 168:4617-4623.
16. Doran H.B.D., Bliese P., Dowling M. Estimating the multilevel Rasch model: with the lme4 package. JStat Softw 2007, 20:1-18.
17. Lee S.Y., Hong M.K. Stent evaluation with optical coherence tomography. Yonsei Med J 2013, 54:1075-1083.
18. Barlis P., Regar E., Serruys P.W., et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J 2010, 31:165-176.
19. Fan C., Kim J.S., Lee J.M., et al. Different vascular healing patterns with various drug-eluting stents in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: optical coherence tomographic findings. Am J Cardiol 2010, 105:972-976.
20. Guagliumi G., Musumeci G., Sirbu V., et al. Optical coherence tomography assessment of invivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2010, 3:531-539.
21. Gutierrez-Chico J.L., van Geuns R.J., Regar E., et al. Tissue coverage ofahydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur Heart J 2011, 32:2454-2463.
22. Kim B.K., Ha J., Mintz G.S., et al. Randomised comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis. EuroIntervention 2014, 9:1389-1397.
23. Choi H.H., Kim J.S., Yoon D.H., et al. Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography. Int J Cardiovasc Imaging 2012, 28:491-497.
24. Kim B.K., Hong M.K., Shin D.H., et al. Anew strategy for discontinuation of dual antiplatelet therapy: REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation (RESET) trial. JAm Coll Cardiol 2012, 60:1340-1348.
25. Silber S., Kirtane A.J., Belardi J., et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J 2014, 35:1949-1956.
26. Kim J.S., Jang I.K., Kim J.S., et al. Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents. Heart 2009, 95:1907-1912.